Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 11/20 | 0.74 |
| ▸ | PDE3A | Q14432 | 11/20 | 0.74 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | BLM | P54132 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | TNNC1 | P63316 | 1/20 | 0.46 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3723998 | 0.85 | PDE3B (1.00) | PDE3BPDE3ASMN1; SMN2MAPTKDM4E | |
| SCHEMBL3723997 | 0.85 | PDE3B (1.00) | PDE3BPDE3ASMN1; SMN2MAPTKDM4E | |
| Dimethylamine SCHEMBL10475180 | 0.83 | PDE3B (0.95) | PDE3BPDE3ASMN1; SMN2MAPTKDM4E | |
| Methylamine SCHEMBL10474969 | 0.83 | PDE3B (0.95) | PDE3BPDE3ASMN1; SMN2MAPTKDM4E | |
| SCHEMBL17446966 | 0.82 | PDE3B (0.59) | PDE3BPDE3ASMN1; SMN2MAPTKDM4E | |
| SCHEMBL17446941 | 0.81 | PDE3B (0.61) | PDE3BPDE3ASMN1; SMN2MAPTKDM4E | |
| SCHEMBL17446921 | 0.81 | PDE3B (0.58) | PDE3BPDE3ASMN1; SMN2MAPTKDM4E | |
| SCHEMBL17446923 | 0.81 | PDE3B (0.78) | PDE3BPDE3ASMN1; SMN2MAPTKDM4E | |
| SCHEMBL17446930 | 0.78 | PDE3B (0.46) | PDE3BPDE3ASMN1; SMN2MAPTKDM4E | |
| SCHEMBL17446948 | 0.78 | PDE3B (0.55) | PDE3BPDE3ASMN1; SMN2MAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9890127-B2 | Compounds and compositions for the treatment of cancer | THE BROAD INSTITUTE, INC. (US) | 2018-02-13 | — | — | US | disclosed |
| US-20160016913-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | THE BROAD INSTITUTE, INC. (US) | 2016-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160016913-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | TP53, RB1, CDK4 | PDE3B 2667/4885PDE3A 2661/4885SMN1; SMN2 3132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.